Demographic, clinical and laboratory characteristics of patients in each outcome group
| Anti-CCP-positive RA (n=48) | Anti-CCP-negative RA (n=53) | Persistent non-RA (n=55) | Resolving arthritis (n=112) | p-Value | |
|---|---|---|---|---|---|
| Gender, n (%) | 0.545 | ||||
| Female | 30 (62.5) | 26 (49.1) | 30 (54.5) | 58 (51.8) | |
| Age (years) | 53.1±13.4 | 60.3±15.8 | 49.4±19.4 | 45.5±15.9 | <0.001 |
| Disease duration (days) | 57±22.7 | 58.9±21.2 | 54.1±22.1 | 45.79±21.4 | 0.001 |
| CRP (mg/dL) | 18 (6–40) | 13 (6–41) | 22 (8–38) | 8 (0–20) | <0.001 |
| ESR (mm/hour) | 29 (20–53) | 23.5 (13–56) | 25 (12–40) | 14 (7–29) | <0.001 |
| DAS28 (CRP) | 4.3±1.3 | 4.3±1.2 | 3.8±1.1 | 3.1±1.2 | <0.001 |
| DAS28 (ESR) | 4.8±1.1 | 4.6±1.2 | 4.1±1.3 | 3.3±1.3 | <0.001 |
| Smoking, n (%) | 0.01 | ||||
| Ever-smoker | 27/47 (57.4) | 32/51 (62.7) | 19/53 (35.8) | 42/103 (40.8) | |
| Never-smoker | 20/47 (42.6) | 19/51 (37.3) | 34/53 (64.2) | 61/103 (59.2) | |
| Anti-CCP positive, n (%) | 48 (100) | 0 (0) | 1 (1.8) | 2 (1.8) | <0.001 |
| RF positive, n (%) | 40/46 (87.0) | 8/52 (15.4) | 5/54 (9.3) | 12/109 (11.0) | <0.001 |
Data are shown as number (percentage), mean±SD or median (IQR) as appropriate.
CCP, cyclic citrullinated peptide; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor.